Dep. Cardiology, School of Medicine and Psychology, University Sapienza of Rome, Ospedale S. Andrea, Rome, Italy.
Int J Cardiol. 2012 May 31;157(2):160-8. doi: 10.1016/j.ijcard.2011.06.066. Epub 2011 Jul 16.
The search for molecules that may contribute to better identify patients at risk for cardiovascular diseases (CVD) represents today an active field in clinical research. Few biomarkers have already been identified as reliable and useful tools in medical decision making, such as cardiac troponin (cTn) and NT-proBNP. At the same time, evidence regarding the possible role of other molecules is piling up. Every new putative biomarker has demonstrated effectiveness in at least one clinical application: cardiovascular risk assessment, diagnosis or outcome prediction. On the other hand, combination of preventive, diagnostic and prognostic implications for the same molecule is expected to improve enormously the usefulness of a biomarker in medicine. We performed a search of the literature looking for circulating molecules found to exert discriminating abilities in all three mentioned clinical applications. The purpose of the present review is to bring to the attention of medical and research communities those biomarkers for which a relevant amount of evidence has been accumulated regarding their potential application in all clinical steps of the cardiovascular continuum. Furthermore, since simultaneous testing of different plasmatic molecules has been proposed as a suitable tool to improve medical decision making, we also discuss feasible associations of biomarkers that promise to be the most effective for cardiovascular risk assessment in the general population and for outcome prediction in patients affected by acute coronary syndrome (ACS) and by heart failure (HF).
寻找可能有助于更好地识别心血管疾病 (CVD) 风险患者的分子,是当今临床研究的一个活跃领域。已经有一些生物标志物被确定为可靠且有用的医学决策工具,如心肌肌钙蛋白 (cTn) 和 NT-proBNP。与此同时,关于其他分子可能作用的证据也在不断增加。每一个新的候选生物标志物都至少在一种临床应用中证明了其有效性:心血管风险评估、诊断或预后预测。另一方面,对于同一分子的预防、诊断和预后意义的结合,有望极大地提高生物标志物在医学中的实用性。我们进行了文献检索,寻找在上述三种临床应用中都具有区分能力的循环分子。本综述的目的是让医学界和研究界注意到那些已经积累了大量关于其在心血管连续体所有临床步骤中潜在应用证据的生物标志物。此外,由于已经提出同时检测不同血浆分子是改善医学决策的一种合适工具,我们还讨论了具有前景的生物标志物联合应用,这些联合应用有望在一般人群的心血管风险评估和急性冠脉综合征 (ACS) 患者和心力衰竭 (HF) 患者的预后预测中发挥最有效的作用。